Nasopharyngeal carcinoma
Conditions
Interventions
1:los platinum
2:cisplatin plus he induction chemotherapy plus los platinum
3:cisplatin chemoradiotherapy
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Between the ages of 18 and 60, male and female; 2. Pathologically confirmed differentiated non-keratinized and undifferentiated non-keratinized carcinomas [according to the pathology of the World Health Organization]; 3. The clinical stage is t3-4n0-2m0, and T3N0 (except T3N0) (except T3N0) (appendix I); 4. Initial treatment of untreated tumor treatment; 5. There are measurable lesions or observable imaging data such as CT and MRI; 6. ECOG PS 0 or 1; 7. The expected survival time is greater than 12 months; 8. The baseline laboratory inspection meets the following criteria: Bone marrow function: WBC is greater than or equal to 4.0 x 10^9/L, and the ANC is greater than or equal to 2.0 x 10^9/ L, and PLT is greater than 100 x 10^9/L Hb is greater than 90g/L. Liver function: total bilirubin is less than or equal to ULN, AST, ALT is less than or equal to ULN x 2.5, alkaline phosphatase is less than or equal to ULN x 5; Renal function: serum creatinine (Cr) is less than or equal to ULN, and Ccr is greater than 60 ml/min (application of Cockcroft-Gault formula); Cardiac function: ecg is basically normal; 9. The patient or his legal representative voluntarily and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are known to be allergic to chemotherapy drugs that may be used; 2. Anti-tumor treatment has been performed, including chemotherapy, radiotherapy and surgery; 3. Previous malignant tumors with other histologic sources, but treated with adequate treatment of cervical carcinoma in situ and basal cell carcinoma or squamous cell carcinoma of the skin; 4. Participated in clinical trials of any research drug in the first 4 weeks of the study; 5. In the first 4 weeks of the group, the surgery or surgical wound has not healed completely; 6. During the first four weeks of the group, the bleeding was greater than that of CTCAE 3; 7. Severe infection requires the use of antibiotics, antifungal or antiviral therapy; 8. Suffer from mental illness and have poor compliance; 9. Cases that the researchers considered inappropriate into the group. 10. Women in pregnancy or lactation;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;PFS;DMFS;LRFS;NRFS; | — |
Countries
China
Contacts
Public ContactHe Xia, Liu Juying
Jiangsu Cancer Hospital
Outcome results
None listed